A study by Plodkowski et al. [130] included a group of patients with pathologically confirmed lung adenocarcinomas of any stage with a RET or ROS1 rearrangement tested via fluorescence in-situ hybridization or next-generation sequencing and a control group of EGFR-positive lung cancers. Here, ROS1 is linked to lung adenocarcinoma.